References
  1. Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004; 364:355-364.
  2. Issaragrisil S. Thai Aplastic Anemia Study Group. Epidemiology of aplastic anemia in Thailand. Int J Hematol. 1999; 70:137-140.
  3. Young, Neal S. Aplastic anemia. The N Eng J Med. 2018; 379(17):1643-1656.
  4. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008; 93(4):518-523.
  5. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48 (1):63-70.
  6. Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med. 1999; 130(3):193-201.
  7. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Eng J Med. 2015; 373(1):35-47.
  8. Kim SY, Lee JW, Lee SE, et al. The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis. Genes Chromosomes Cancer. 2010;49(9):844-850.
  9. Mikhailnova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996; 81(5): 418-422.
  10. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overexpressed in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002; 100(5):1570-1574.
  11. Narita A, Kojima S. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. Int J Haematol. 2016; 104:153-158.
  12. Wang C, Zhang T, Wang Y, et al. The shortening telomere length of T-lymphocytes maybe associated with hyper-function in severe aplastic anemia. Mol Med Rep. 2018; 17(1):1015-1021.
  13. Tichelli A, Schrezenmeier H, Socie G, et al. A randomised controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow transplantation. Blood.2011; 117(17):4434-4441.
  14. Tjon JM-L, de Groot MR, Sypkens Smit SMA, et al. Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anemia. Br J haematol. 2016; 180(3):459-462.
  15. Contejean A, Resche-Rigon M, Tamburini J, et al. Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018; 104(2):256-262.
  16. Killick SB, Cavenagh JD, Davies JK, et al. Low dose antithymocyte globulin for the treatment of older patients with aplastic anemia. Leuk Res. 2006; 30(12):1517-20.
  17. Hwang YY, Gill Harinder, Chan TSY, et al. Eltrombopag in the management of aplastic anemia: real world experience in a non-trial setting. Hematology.2018; 23(7): 399-404.
  18. Bacigalupo A. How I treat aplastic anemia. Blood. 2017; 129(11): 1428-1436.